Turning Point Therapeutics Inc

Turning Point Therapeutics — Technical Presentation (August 2020)

17 slides from Turning Point Therapeutics's technical presentation, Aug 19, 2020

  1. Slide 1: TRIDENT-1 Phase 2 Study of Repotrectinib: Early Interim Data Update

    TRIDENT-1 Phase 2 Study of Repotrectinib: Early Interim Data Update August 19, 2020 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, business strategy and plans, r

  3. Slide 3: Our Vision Drives our Strategy

    Our Vision Drives our Strategy Pipeline Expansion Clinical Excellence Leadership in Precision Oncology Potential for Best-in-Class Products Addressing Patients with High Unmet Need in TKI-Naïve and Resistance Settings Deep Oncology Development Expertise Rapid Clinical Proof-of-Concept Data Therapeut

  4. Slide 4: Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy

    Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy in TKI-Naïve and Treatment Resistance Settings Highly potent, structurally differentiated: small (low molecular weight), compact, with a rigid 3D macrocycle Designed to bind completely inside the ATP pocket even in the presence of

  5. Slide 5: Phase 1 data and comparator therapies footnotes

    ¹ Based on Phase 1 data as of July 22, 2019 cutoff; TKI-Naïve patients treated at multiple repotrectinib dose levels; TKI-pretreated patients with 1 prior TKI and 1 prior chemotherapy treated at repotrectinib dose of 160 mg or above; intracranial patients with 1 prior TKI and at least one prior line

  6. Slide 6: Pivotal Phase 2 TRIDENT-1 Study Ongoing

    Pivotal Phase 2 TRIDENT-1 Study Ongoing Single-agent repotrectinib studied in six cohorts (n=~320) Starting dose at 160 mg QD, which may be increased after 14 days to 160 mg BID based on tolerability Fast Track Designation granted for TKI-naïve and TKI-pretreated ROS1+ advanced NSCLC patients *Patie

  7. Slide 7: TRIDENT-1 Phase 2 Study: Early Interim Data Summary

    TRIDENT-1 Phase 2 Study: Early Interim Data Summary N=39 Patients1 Data cutoff date, 10 July 2020 Analysis includes EXP-1, EXP-2, EXP-3, EXP-4, EXP-6, Other Enrolled across 6 countries All patients were followed for at least one post-baseline scan evaluated by RECIST v1.1 by Investigator Responses (

  8. Slide 8: TRIDENT-1 Phase 2 Study: Early Interim Data Summary by cohort

    TRIDENT-1 Phase 2 Study: Early Interim Data Summary Phase 2 (N=391) Cohort ROS1+ TKI-Naïve (EXP-1: N=7) ROS1+ TKI Pretreated 1 Prior TKI with prior platinum-based chemotherapy (EXP-2: N=5) ROS1+ TKI Pretreated 1 Prior TKI without prior platinum-based chemotherapy (EXP-4: N=6) ROS1+ TKI-Pretreated: 2

  9. Slide 9: TRIDENT-1 Efficacy Overview – Early Phase 2 Data Compared to Phase 1

    TRIDENT-1 Efficacy Overview – Early Phase 2 Data Compared to Phase 1 Phase 2 (N=391) Efficacy by Physician Assessment ROS1+ TKI-Naïve (EXP-1: N=7) ROS1+ TKI Pretreated 1 Prior TKI with prior platinum-based chemotherapy (EXP-2: N=5) ROS1+ TKI Pretreated 1 Prior TKI without prior platinum-based chemot

  10. Slide 10: ROS1+ TKI Naïve Advanced NSCLC Patients in TRIDENT-1

    ROS1+ TKI Naïve Advanced NSCLC Patients in TRIDENT-1 (EXP-1 + Phase 1) ^Patient achieved an unconfirmed partial response after the data cutoff date and remains on treatment awaiting a confirmatory scan. uPR is not counted in cORR calculation. Phase 2 Data cutoff of 10 July 2020, responses confirmed

  11. Slide 11: ROS1+ TKI-Pretreated: One Prior TKI with Prior Chemotherapy

    ROS1+ TKI-Pretreated Advanced NSCLC Patients in TRIDENT-1: One Prior TKI with Prior Platinum-Based Chemotherapy (EXP-2 + Phase 1) Patient with cCR had a G2032R solvent-front mutation after prior treatment with entrectinib Phase 2 Data cutoff of 10 July 2020, responses confirmed by Physician Assessme

  12. Slide 12: ROS1+ TKI-Pretreated: One Prior TKI without Prior Chemotherapy

    ROS1+ TKI-Pretreated Advanced NSCLC Patients in TRIDENT-1: One Prior TKI without Prior Platinum-Based Chemotherapy (EXP-4 + Phase 1) Phase 2 Data cutoff of 10 July 2020, responses confirmed by Physician Assessment Phase 1 Data cutoff of 22 July 2019, responses confirmed by Blinded Independent Centra

  13. Slide 13: ROS1+ TKI-Pretreated: Two Prior TKIs without Prior Chemotherapy

    ROS1+ TKI-Pretreated Advanced NSCLC Patients in TRIDENT-1 : Two Prior TKIs without Prior Platinum-Based Chemotherapy (EXP Other + Phase 1) Phase 2 Data cutoff of 10 July 2020, responses confirmed by Physician Assessment Phase 1 Data cutoff of 22 July 2019, responses confirmed by Blinded Independent

  14. Slide 14: NTRK+ TKI-Pretreated Advanced Solid Tumor Patients in TRIDENT-1

    NTRK+ TKI-Pretreated Advanced Solid Tumor Patients in TRIDENT-1 (EXP-6 + Phase 1) Confirmed ORR (cORR) (95% CI) Duration of Response Phase 2 Data cutoff of 10 July 2020, responses confirmed by Physician Assessment per RECIST Phase 1 Data cutoff of 22 July 2019, responses confirmed by Blinded Indepen

  15. Slide 15: Safety: TEAEs and TRAEs in All Treated Patients

    All Treated Patients (n=39) TEAEs (≥10% of patients) TRAEs All Grades Grade 3 Grade 4 Grade 31 Grade 4 Adverse Event n (%) n (%) n (%) n (%) n (%) Dizziness 24 (61.5) – – --- – Fatigue 15 (38.5) 1 (2.6) – 1 (2.6) – Constipation 13 (33.3) – – – – Dysgeusia 13 (33.3) – – – – Dyspnea 11 (28.2) 1 (2.6)

  16. Slide 16: Planned Updates to Phase 2 TRIDENT-1 Study Design

    Planned Updates to Phase 2 TRIDENT-1 Study Design Planned Updates Noted in Yellow Boxes ROS1+ Advanced NSCLC NTRK+ Advanced Solid Tumors EXP-1 ROS1 TKI-Naïve (n=55) EXP-2 1 Prior ROS1 TKI AND 1 Platinum-Based Chemotherapy (n=60) EXP-3* 2 Prior ROS1 TKIs AND No Prior Chemotherapy (n=40) EXP-4 1 Prior

  17. Slide 17: TRIDENT-1 Phase 2 Data Update – Key Takeaways

    TRIDENT-1 Phase 2 Data Update – Key Takeaways Early, interim data in 39 patients from ongoing Phase 2 study reaffirm repotrectinib as potentially best-in-class therapy Wider global population: Patients enrolled across 6 countries as compared to 2 countries in the Phase 1 portion Dose-titration appro

Turning Point Therapeutics — Technical Presentation (August 2020) on 6ix